Medacta International, the privately held family-owned global leader in the design of innovative joint replacement and spine surgery products, announced clearance by the FDA for its Short Humeral Diaphysis, which is utilized with the Medacta Shoulder System.
The Short Humeral Diaphysis is an implantable device that replaces the humeral side of the gleno-humeral joint and is intended for use with the Medacta Shoulder System as an alternative to the Standard Humeral Diaphysis. The Short Humeral Diaphysis is indicated for primary and reverse shoulder replacement in patients suffering from severe arthropathy or a grossly deficient rotator cuff. Through a reduction in device length, the corresponding procedure minimizes the violation of the humeral intramedullary canal (IM). The device is manufactured from titanium alloy and will be offered in 11 sizes to provide a patient-matched fit.
“Medacta is constantly looking to expand its product offerings to accommodate the largest group of unique patient anatomies as possible,” says Francesco Siccardi, executive vice president of Medacta International. “We’ve experienced a very positive response to our recent expansion into the shoulder market and are looking to build on that success. The addition of the Short Humeral Diaphysis to the Medacta Shoulder System means that surgeons will be able to achieve a more personalized fit for more patients, improving the patient and surgeon experience.”